Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) were up 5.7% during trading on Monday . The company traded as high as $24.04 and last traded at $23.85. Approximately 562,800 shares were traded during mid-day trading, an increase of 131% from the average daily volume of 243,719 shares. The stock had previously closed at $22.56.

A number of analysts have commented on CNCE shares. Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 price objective on shares of Concert Pharmaceuticals in a report on Sunday, October 22nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Concert Pharmaceuticals in a report on Monday, September 18th. Zacks Investment Research downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Mizuho started coverage on shares of Concert Pharmaceuticals in a report on Thursday, October 26th. They issued a “buy” rating and a $23.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Concert Pharmaceuticals has a consensus rating of “Hold” and an average price target of $23.00.

In related news, insider Ryan Lynch sold 3,500 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $14.51, for a total transaction of $50,785.00. Following the completion of the transaction, the insider now owns 9,500 shares of the company’s stock, valued at approximately $137,845. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 331,916 shares of the stock in a transaction that occurred on Thursday, October 19th. The shares were bought at an average cost of $15.84 per share, with a total value of $5,257,549.44. The disclosure for this purchase can be found here. Corporate insiders own 10.10% of the company’s stock.

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in shares of Concert Pharmaceuticals during the 3rd quarter worth approximately $153,000. Alliancebernstein L.P. purchased a new position in shares of Concert Pharmaceuticals during the 2nd quarter worth approximately $174,000. State of Wisconsin Investment Board purchased a new position in shares of Concert Pharmaceuticals during the 2nd quarter worth approximately $181,000. The Manufacturers Life Insurance Company boosted its position in shares of Concert Pharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 287 shares during the period. Finally, Airain ltd purchased a new position in shares of Concert Pharmaceuticals during the 2nd quarter worth approximately $215,000. 65.36% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Concert Pharmaceuticals (CNCE) Trading Up 5.7%” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2017/12/06/concert-pharmaceuticals-cnce-trading-up-5-7.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.